Remove 2022 Remove Healthcare Remove Pharmaceutical manufacturing
article thumbnail

Sandoz and Teva achieve first-of-a-kind manufacturing certification

European Pharmaceutical Review

According to the BSI, all manufacturers of these products are eligible for the AMR certification to gain the BSI Kitemark , which involves an initial evaluation against the requirements of a designated international standard, published in June 2022.

article thumbnail

India joins mission to harmonise pharmacopoeial standards

European Pharmaceutical Review

Eur.) , Japanese Pharmacopoeia (JP), and the US Pharmacopeia (USP) in 1989. Thus, a key aim for the PDG is to harmonise select pharmacopoeial standards.

Medicine 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New AMR certification launched for antibiotic manufacturers

European Pharmaceutical Review

BSI, a UK standards body, developed the new certification to the Antibiotic Manufacturing Standard published in June 2022.

article thumbnail

Tackling fake pharmaceuticals: an industry united against counterfeit products

European Pharmaceutical Review

Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. Essentially, both counterfeit and falsified medicines pose risks to public health and threaten to undermine the healthcare system and pharmaceutical industry. About the author.

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

FDI experts at Investment Monitor have highlighted the following list of factors as most important to life sciences companies considering a greenfield investment in 2022: labour, education, industry clusters, domestic market, infrastructure, business environment, costs and quality of life. appeared first on Pharmaceutical Technology.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines.

article thumbnail

Everything You Need to Know About Market Access in China

PM360

Given China’s status as the world’s second most populous nation and an economic powerhouse, it represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. From 2017 to 2022, the Chinese market witnessed a growth rate of 5.3%, compared to the average market growth of 6.6% in the U.S.

Marketing 105